Bladder preservation trial for muscle-invasive bladder cancer with variant histology
Part of Cancer clinical trials.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have muscle-invasive bladder cancer with a variant histology type.
- Your cancer should be at stage cT2 to cT4 and not have spread to lymph nodes or distant organs.
- You must have had a TURBT procedure and a CT scan of your chest, abdomen, and pelvis, or a PET scan to confirm your diagnosis.
- You must be willing to give written informed consent and follow the study requirements.
- You cannot have diffuse CIS (a widespread type of carcinoma in situ) in your pathology report.
- You cannot have hydronephrosis (kidney swelling) on both sides, only one side is allowed if present.
- You must not have had radiation therapy to your pelvis before.
- You must not have had systemic therapy (like chemotherapy) for muscle-invasive bladder cancer before.
- You cannot have another active cancer, unless it was treated more than 5 years ago and you have no evidence of disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
This trial tests a new treatment approach using MRI to guide bladder preservation for patients with muscle-invasive bladder cancer. The goal is to treat the cancer with chemotherapy and radiation instead of removing the bladder, potentially allowing you to keep your bladder while fighting the cancer.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This study collects information from people with muscle-invasive bladder cancer who have had chemotherapy or immunotherapy and then decided not to have their bladder removed. It looks at different ways to preserve the bladder and how well those approaches work.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.